Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. 2009

Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
Serviço Integrado de Ginecologia de Cachoeirinha e Alvorada-SIGAC, Instituto de Cardiologia-Fundação Universitária de Cardiologia (IC-FUC) de Porto Alegre, Brazil. anschau@terra.com.br

To investigate the expression of p16(INK4a) in cervical carcinoma and its relation to the transition of carcinoma in situ to invasive carcinoma, and its role in recurrence of cervical lesions as well, a series of 90 patients with cervical carcinoma (49 with in situ lesion and 41 with invasive lesion) were selected from July 2001 and September 2002. Groups with in situ and invasive lesions were paired for a series of risk variables for cervical cancer and followed up for 60 months. The follow-up visits occurred every 6 months in the first three years and annually up to the fifth year. It was observed that 87.9% of the patients with invasive lesion showed overexpression of p16(INK4a), in comparison with 37.6% of those with in situ lesion (X(2): 13.68; 2 df; p=0.0002; OR: 12.08), demonstrating overexpression of p16(INK4a) as a risk of invasion of the basal layer by dysplastic cells. We also observed an association between overexpression of p16(INK4a) and staging of cancer (X(2): 18.38; 6 df; p=0.0003). A prospective analysis, when controlled for interaction with cervical lesion groups (by Cox regression), demonstrated a risk of recurrence of 4.83 times attributed to overexpression of p16(INK4a), albeit not statistically significant (p=0.14).

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
December 2016, Papillomavirus research (Amsterdam, Netherlands),
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
June 2016, Journal of cancer prevention,
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
November 2008, European journal of obstetrics, gynecology, and reproductive biology,
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
September 2006, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica,
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
July 2009, Reproductive sciences (Thousand Oaks, Calif.),
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
July 2004, American journal of clinical pathology,
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
March 2001, Experimental cell research,
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
July 2013, Cell cycle (Georgetown, Tex.),
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
October 2011, Human pathology,
Fernando Anschau, and Virgínia Minghelli Schmitt, and Ana Paula Franco Lambert, and Manoel Afonso Guimarães Gonçalves, and Denise Cantarelli Machado
September 2004, Cancer letters,
Copied contents to your clipboard!